A multivariate analysis of patients with glioma: a treatment outcome and prognostic factor for survival.
OBJECTIVE
To evaluate the treatment outcome and to examine the influence of factors on survival of patients with glioma.


METHODS
One hundred and eighty-nine patients were included. Data on the patient's age, sex, KPS score, tumor location and survival time were collected and analyzed.


RESULTS
Tumor grade and age had effect on survival of the patients. The median survival time (MST) of patients with grade II-IV glioma was 80.0, 20.0 and 9 months, respectively. Only the tumor site had influence on survival of patients with grade II glioma. In patients with grade III glioma, only KPS score had an impact on survival. In patients with grade IV glioma, none of the factors had an effect on survival.


CONCLUSIONS
The treatment outcome of the patients in Chulalongkorn University is comparable to other series. Multivariate analysis identified factors that had influence on survival of the patients.
Siangprasertkij
Chaiyot
C
Division of Neurological Surgery, Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Navalitloha
Yot
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005910:Glioma / Q000188:drug therapy / Q000401:mortality* / Q000532:radiotherapy; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D000077204:Temozolomide; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide